PTC Therapeutics, Inc. (PTCT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$68.97+1.25%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PTCT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -25.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 20.2% |
Growth built into the price is above our model estimate.
The price assumes 45.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
PTCT — director transition
Dated 2026-07-30
Director — Hege Sollie-Zetlmayer: Ms. Hege Sollie-Zetlmayer was appointed to the board of directors, filling a vacancy.
Why it matters: The meeting will address the Phase 2 results and a possible faster approval path. FDA feedback can clarify the next step.
Watch forPTC holds the FDA Type C meeting in Q1 2027 and reports a clear path to seek accelerated approval.
Also watch forThe meeting moves beyond Q1 2027. Or PTC says FDA feedback does not support an accelerated approval path.
Why it matters: PTC raised its product revenue range to $960 million to $990 million. The year-end result tests that higher bar.
Supportive ifFull-year 2026 product revenue is at least $960 million, within or above the raised range.
Worry ifFull-year 2026 product revenue is below $960 million, or the company lowers its $960 million to $990 million range.
Why it matters: The filing is the next stated step toward a possible 2027 launch. A delay would push that path back.
Supportive ifPTC submits the ST-920 BLA to the FDA by December 31, 2026.
Worry ifPTC does not submit the BLA by December 31, 2026, or announces a later filing date.
Why it matters: Management said strong Q3 sales put PTC on track for cash flow breakeven this year. The year-end report can confirm whether it happened.
Supportive ifPTC reports cash flow from operations at or above zero for full-year 2026.
Worry ifPTC reports negative cash flow from operations for full-year 2026, or pushes the breakeven goal beyond 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$134 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $425 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,385 loss on $10,000 · 33.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Sephience drove much of the recent product growth. Q4 revenue will test whether the launch keeps gaining pace.
Watch forQ4 Sephience revenue tops $182 million, the Q3 level, and active patient count rises above 2,000.
Also watch forQ4 Sephience revenue falls below $182 million or active patient count drops below 2,000.